tSense

Sex hormone levels, including testosterone, are important for men's vitality and women's menopause management, but regular tracking has been difficult due to reliance on blood tests.

Frequent hospital visits are required for monitoring male hypogonadism or female hormone therapy, and results are delayed, making real-time adjustments difficult. There is also a lack of comprehensive analysis methods for stress hormones such as cortisol, which fluctuate greatly on a daily basis.

tSense accurately calculates testosterone concentration from saliva using a special chemical sensor + AI analysis. It extracts signals from a small amount of saliva through three patent-pending technologies and delivers results within 3 minutes.

The device is linked via Bluetooth to Nutrix's gSense AI healthcare platform, which analyzes measurement trends and provides personalized insights (e.g., differences between morning vs. evening levels, lifestyle influences). This non-invasive method, which only requires spitting into the device, eliminates pain and hygiene concerns, and enables self-frequency measurement, aiding in fine-tuning dosage during hormone therapy.

Also, when used with Nutrix's existing cortiSense (non-invasive cortisol sensor), it becomes the world's first multi-hormone monitoring solution, which can be widely used for men's health, athlete performance, and stress management.

Individuals undergoing male hormone therapy, middle-aged men, menopausal women, and those in the fitness and sports fields purchase and use it (B2C). A B2B2C channel is also expected, where anti-aging clinics and fitness centers adopt it for customer management.

There is a high global need due to the growing interest in hormone healthcare. It can be used even in areas with low medical accessibility, making it possible to target developing country markets.

However, medical device regulations are a variable, and it is important to prove reliability to overcome the limitations of saliva-based testing (e.g., food contamination). Nutrix has already gained recognition with the previous year's CES award (cortiSense), accelerating investment attraction and product commercialization, and is expected to continue expanding into a multi-hormone platform.

Recognized as an innovative biosensor in the CES digital health category. There was praise that "major health information is now obtained from saliva, not blood," and the potential to change the landscape of men's health management was mentioned.

However, it is still in the prototype stage, and clinical validation and mass production are considered challenges. Overall, the technology concept is attractive, but it is evaluated as an R&D stage that requires commercialization verification.